20/20 Biolabs, Inc. (AIDX) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
20/20 Biolabs, Inc. (AIDX) stock forecast summary
On Oct. 14, 2026, AIDX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
20/20 Biolabs, Inc. is a small-cap company with a market capitalization of $4M.
A per-ticker accuracy statistic for AIDX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AIDX included.
Follow AIDX freeAIDX price chart and AI forecast
How AIDX ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
20/20 Biolabs, Inc. (AIDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Testing Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | AIDX | Rank |
|---|---|---|
| Market Cap | $4M | – |
| P/B Ratio | 2.77x | – |
| Book Value/Share | $0.13 | – |
Profitability & Margins
| Metric | AIDX | Rank |
|---|---|---|
| ROE | -342.5% | – |
| ROA | -90.7% | – |
| Net Margin | -263.5% | – |
Financial Health
| Metric | AIDX | Rank |
|---|---|---|
| Current Ratio | 1.99x | – |
| Quick Ratio | 1.95x | – |
| D/E Ratio | 1.83x | – |
| Financial Leverage | 3.78x | – |
| Working Capital | $3M | – |
Income Statement
| Metric | AIDX | Rank |
|---|---|---|
| Net Income | -$5M | – |
Dividend & Shareholder Information
| Metric | AIDX | Rank |
|---|---|---|
| Shares Outstanding | 13M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5M | |
| Cash & Short-term Investments | $5M | 99.3% of assets |
| Accounts Receivable | $290K | 6.3% of assets |
| Inventory | $110K | 2.4% of assets |
| Total Liabilities | $3M | 64.6% of assets |
| Short-term Debt | $2M | 33.2% of assets |
AIDX quarterly financials and insider trading
20/20 Biolabs, Inc. (AIDX) industry peers
Companies classified under the same SEC industry code as 20/20 Biolabs, Inc. (Services-Testing Laboratories): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere AIDX sits on the market map
20/20 Biolabs, Inc. (AIDX) stock news
Loading...
20/20 Biolabs, Inc. (AIDX) stock forecast FAQ
What is the 20/20 Biolabs, Inc. (AIDX) stock forecast?
On Oct. 14, 2026, AIDX is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
How accurate are 20/20 Biolabs, Inc. stock predictions?
A per-ticker accuracy statistic for AIDX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are 20/20 Biolabs, Inc. forecasts updated?
20/20 Biolabs, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are 20/20 Biolabs, Inc.'s industry peers?
4 issuers in our coverage, AIDX included, share the SEC industry code Services-Testing Laboratories. The largest are: Ul Solutions Inc. (ULS), Neogenomics Inc (NEO), Hypha Labs, Inc. (FUNI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.